See more : Vantage Towers AG (VTWRF) Income Statement Analysis – Financial Results
Complete financial analysis of Immunome, Inc. (IMNM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Immunome, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Johnson Controls International plc (0Y7S.L) Income Statement Analysis – Financial Results
- Ansal Housing Limited (ANSALHSG.NS) Income Statement Analysis – Financial Results
- KUBOTEK Corporation (7709.T) Income Statement Analysis – Financial Results
- Wisr Limited (WZR.AX) Income Statement Analysis – Financial Results
- Intercontinental International Real Estate Investment Company (INTERCO.AT) Income Statement Analysis – Financial Results
Immunome, Inc. (IMNM)
About Immunome, Inc.
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 14.02M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 22.93M | 631.00K | 755.00K | 755.00K | 615.00K | 521.00K |
| Gross Profit | -8.91M | -631.00K | -755.00K | -755.00K | -615.00K | -521.00K |
| Gross Profit Ratio | -63.54% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 80.80M | 23.27M | 14.11M | 7.49M | 8.82M | 6.88M |
| General & Administrative | 19.66M | 13.63M | 11.09M | 4.78M | 1.53M | 866.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 19.66M | 13.63M | 11.09M | 4.78M | 1.53M | 866.00K |
| Other Expenses | 0.00 | 0.00 | 503.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 122.82M | 36.90M | 25.20M | 12.26M | 10.35M | 7.74M |
| Cost & Expenses | 123.55M | 36.90M | 25.20M | 12.26M | 10.35M | 7.74M |
| Interest Income | 2.72M | 5.00K | 10.00K | 1.00K | 10.00K | 39.00K |
| Interest Expense | 0.00 | 5.00K | 10.00K | 38.00K | 106.00K | 141.00K |
| Depreciation & Amortization | 728.00K | 631.00K | 755.00K | 755.00K | 615.00K | 521.00K |
| EBITDA | -28.27M | -36.27M | -23.95M | -17.04M | -9.72M | -7.18M |
| EBITDA Ratio | -201.68% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -109.53M | -36.90M | -25.20M | -12.26M | -10.35M | -7.74M |
| Operating Income Ratio | -781.35% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.72M | 5.00K | 493.00K | -5.58M | -96.00K | -102.00K |
| Income Before Tax | -106.81M | -36.90M | -24.71M | -17.84M | -10.44M | -7.85M |
| Income Before Tax Ratio | -761.92% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 617.00K | -242.00K | -717.00K | 106.00K | 39.00K |
| Net Income | -106.81M | -37.51M | -24.47M | -17.12M | -10.55M | -7.85M |
| Net Income Ratio | -761.92% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -5.38 | -3.09 | -2.12 | -1.69 | -1.84 | -7.18 |
| EPS Diluted | -5.38 | -3.09 | -2.12 | -1.69 | -1.84 | -7.18 |
| Weighted Avg Shares Out | 19.84M | 12.13M | 11.54M | 10.11M | 5.74M | 1.09M |
| Weighted Avg Shares Out (Dil) | 19.84M | 12.13M | 11.54M | 10.11M | 5.74M | 1.09M |
Immunome: The Morphimmune Merger And The Pipeline
IMNM is set to merge with Morphimmune, pending a shareholder vote on September 29. The current CEO of Morphimmune, Clay Siegall, would become the new CEO of IMNM. Siegall co-founded and led Seagen for over 20 years. Immunome intends to...
Immunome Reports Second Quarter 2023 Financial Results
EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics to improve patient care, today reported financial results for the second quarter ended June 30, 2023...
Shareholder Alert: Ademi LLP investigates whether Immunome, Inc. has obtained a Fair Price in its Private Placement and its transaction with Morphimmune
MILWAUKEE, June 30, 2023 /PRNewswire/ — Ademi LLP is investigating Immunome (Nasdaq: IMNM) for possible breaches of fiduciary duty and other violations of law in its private placement and its transaction with Morphimmune. Click here to learn how to join...
Immunome (IMNM) Surges on Merger Agreement With Morphimmune
Immunome's (IMNM) shares rise following its announcement to merge with Morphimmune. The synergy will help strengthen the development of oncology therapies.
Recent Price Trend in Immunome, Inc. (IMNM) is Your Friend, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Immunome, Inc. (IMNM) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Immunome to Present at 13th Annual World ADC London Conference
EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop antibody therapeutics to improve patient care, today announced that Matthew Robinson, Ph.D., Chief Technology Officer, will present at the...
Immunome: Clinical Data With A COVID Therapeutic And The AbbVie Collaboration
Topline data from Immunome's phase 1b trial of its COVID antibody drug, IMM-BCP-01, have led the company to look for a partner for further development. Even if IMNM can't find a partner for IMM-BCP-01, a new collaboration agreement with ABBV...
AbbVie Briefly Breaks Out After Tapping Immunome In $30 Million Cancer Deal
AbbVie stock briefly broke out Friday after the company signed a $30 million deal with small biotech Immunome in antibody development. The post AbbVie Briefly Breaks Out After Tapping Immunome In $30 Million Cancer Deal appeared first on Investor's Business...
AbbVie and Immunome Partner to Find New Cancer Treatments
Immunome and AbbVie announced a worldwide collaboration and option agreement to discover up to 10 new antibody-target pairs for treating three specific types of tumors using Immunome's technology.
AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets
- Multi-year collaboration to identify up to 10 novel target-antibody pairs leveraging Immunome's Discovery Engine - Immunome to receive $30M upfront payment with potential for further platform access and option payments as well as development, commercial, and sales-based milestones, and...
Source: https://incomestatements.info
Category: Stock Reports